Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats

Pharmacological Research

Volumn 61, Issue 2, 2010, Pages 129-135

  Cermanova, Jolana ^a   Fuksa, Leos ^a   Brcakova, Eva ^a   Hroch, Milos ^a   Kucera, Otto ^a   Kolouchova, Gabriela ^a   Hirsova, Petra ^a   Malakova, Jana ^a   Staud, Frantisek ^b   Martinkova, Jirina ^a   Cervinkova, Zuzana ^a   Micuda, Stanislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Amiodarone; Cyp3a2; Mdr1; Mdr2; Mrp2; Rhodamine 123

Indexed keywords

AMIODARONE; BILIRUBIN GLUCURONIDE; CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RHODAMINE 123;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG ELIMINATION; DRUG MECHANISM; KIDNEY; KIDNEY CLEARANCE; LIVER; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; UPREGULATION;

ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILIRUBIN; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELLS, CULTURED; DRUG INTERACTIONS; HEPATOCYTES; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; RATS; RATS, WISTAR; RHODAMINE 123; UP-REGULATION;

EID: 73949097567     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.08.005     Document Type: Article

References (32)

1. Lesko L.J. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet 17 (1989) 130-140
2. Roden D.M. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol 72 (1993) 45F-50F
3. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., and Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28 (2000) 1303-1310
4. Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., and Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49 (2000) 244-253
5. Yamreudeewong W., DeBisschop M., Martin L.G., and Lower D.L. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 26 (2003) 421-438
6. Weinhouse E., Kaplanski J., Zalzstein E., Genchik G., Colton D., and Nudel D. Mechanisms of digoxin-amiodarone interaction in the rat. Proc Soc Exp Biol Med 188 (1988) 96-102
7. Arboix M., Paz O.G., Colombo T., and D'Incalci M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther 281 (1997) 1226-1230
8. Kakumoto M., Takara K., Sakaeda T., Tanigawara Y., Kita T., and Okumura K. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull 25 (2002) 1604-1607
9. Katoh M., Nakajima M., Yamazaki H., and Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12 (2001) 505-513
10. Funakoshi S., Murakami T., Yumoto R., Kiribayashi Y., and Takano M. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci 94 (2005) 1196-1203
11. Kodawara T., Masuda S., Wakasugi H., Uwai Y., Futami T., Saito H., et al. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 19 (2002) 738-743
12. Daoudaki M., Fouzas I., Stapf V., Ekmekcioglu C., Imvrios G., Andoniadis A., et al. Cyclosporine a augments P-glycoprotein expression in the regenerating rat liver. Biol Pharm Bull 26 (2003) 303-307
13. Kageyama M., Namiki H., Fukushima H., Terasaka S., Togawa T., Tanaka A., et al. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 28 (2005) 130-137
14. Micuda S., Fuksa L., Mundlova L., Osterreicher J., Mokry J., Cermanova J., et al. Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly. Clin Exp Pharmacol Physiol 34 (2007) 296-303
15. Cervinkova Z., Lotkova H., Krivakova P., Rousar T., Kucera O., Tichy L., et al. Evaluation of mitochondrial function in isolated rat hepatocytes and mitochondria during oxidative stress. Altern Lab Anim 35 (2007) 353-361
16. Fuksa L., Brcakova E., Cermanova J., Hroch M., Chladek J., Kolouchova G., et al. Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. Biopharm Drug Dispos 29 (2008) 289-299
17. Micuda S., Brcakova E., Fuksa L., Cermanova J., Osterreicher J., Hroch M., et al. P-glycoprotein function and expression during obstructive cholestasis in rats. Eur J Gastroenterol Hepatol 20 (2008) 404-412
18. Benet L.Z., Cummins C.L., and Wu C.Y. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4 (2003) 393-398
19. Koziolek M.J., Riess R., Geiger H., Thevenod F., and Hauser I.A. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 60 (2001) 156-166
20. Garcia del M.R., O'Valle F., Andujar M., Aguilar M., Lucena M.A., Lopez-Hidalgo J., et al. Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study. Am J Pathol 146 (1995) 398-408
21. del Moral R.G., Andujar M., Ramirez C., Gomez-Morales M., Masseroli M., Aguilar M., et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol 151 (1997) 1705-1714
22. Jette L., Potier M., and Beliveau R. P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. Biochemistry 36 (1997) 13929-13937
23. Trauner M., Fickert P., and Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27 (2007) 77-98
24. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno Y., and Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol Appl Pharmacol 229 (2008) 290-299
25. Pal D., and Mitra A.K. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 1 (2006) 323-339
26. Koch I., Weil R., Wolbold R., Brockmoller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 (2002) 1108-1114
27. Morales A.I., Barata J.D., Bruges M., Arevalo M.A., Gonzalez de Buitrago J.M., Palma P., et al. Acute renal toxic effect of amiodarone in rats. Pharmacol Toxicol 92 (2003) 39-42
28. Salgado H.C., Simoes G.M., Santana F.V., Dias dS V., Salgado M.C., and Fazan Jr. R. Negative inotropic and lusitropic effects of intravenous amiodarone in conscious rats. Clin Exp Pharmacol Physiol 34 (2007) 870-875
29. Nademanee K., Kannan R., Hendrickson J., Ookhtens M., Kay I., and Singh B.N. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 4 (1984) 111-116
30. de Lannoy I., and Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189 (1992) 551-557
31. van der Graaf W.T., de Vries E.G., Uges D.R., Nanninga A.G., Meijer C., Vellenga E., et al. In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 48 (1991) 616-622
32. Genne P., Coudert B., Pelletier H., Girardot C., Martin F., and Chauffert B. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer Res 9 (1989) 1655-1659